On September 27, 2018, the United States Drug Enforcement Administration (DEA) announced that it would reschedule Epidiolex, a CBD-based, cannabis-derived drug used to treat forms of severe juvenile epilepsy, from a Schedule I substance to a Schedule V substance. The DEA defines Schedule V substances as “drugs, substances, or chemicals defined as drugs with lower potential for abuse than Schedule IV and consist[ing] of preparations containing limited quantities of certain narcotics.” The ruling also pertains to any “FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols.” Manufactured by GW Pharmaceuticals (GWPH), sales of Epidiolex are expected to begin immediately.